FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns an antibody-drug conjugate for the treatment of a subject with an EDB+ FN-expressing malignant neoplasm containing (a) an antibody or its antigen-binding fragment that binds to an extra-domain B of fibronectin (EDB+ FN), (b) a vc linker and (c) a cytotoxic agent, where the constant region of a heavy chain contains an embedded cysteine residue at position 290 (K290C) according to the EU index numeration by Kabat, and where the constant region of a light chain contains an embedded cysteine residue at position 183 (κK183C) according to the Kabat numeration. The group of inventions also concerns a pharmaceutical composition for the treatment of EDB+ FN-expressing malignant neoplasm containing the specified antibody-drug conjugate and a pharmaceutically acceptable carrier; a method for obtaining the specified antibody-drug conjugate.
EFFECT: group of inventions provides treatment of a subject with an EDB+ FN-expressing malignant neoplasm.
25 cl, 11 dwg, 25 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
